Cargando…

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

BACKGROUND: While providers are challenged with treatment decisions during the coronavirus disease 2019 (COVID-19) crisis, decision making ultimately falls in the hands of patients—at present, their perspective is poorly understood. OBJECTIVE: To ascertain renal cell carcinoma (RCC) patients’ perspe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staehler, Michael, Battle, Dena, Pal, Sumanta Kumar, Bergerot, Cristiane Decat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association of Urology. Published by Elsevier B.V. 2021
Materias:	Kidney Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486070/ https://www.ncbi.nlm.nih.gov/pubmed/32943372 http://dx.doi.org/10.1016/j.euf.2020.09.002

Ejemplares similares

COVID-19 and financial toxicity in patients with renal cell carcinoma
por: Staehler, Michael D., et al.
Publicado: (2020)

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy
por: Abdelsalam, Mohamed E., et al.
Publicado: (2023)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma
por: Tanaka, Hajime, et al.
Publicado: (2022)

Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions
por: Patel, Hiten D., et al.
Publicado: (2022)

Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
por: Davidsson, Sabina, et al.
Publicado: (2020)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
por: Almdalal, Tarik, et al.
Publicado: (2022)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Patient-Reported Outcomes in Early Phase Clinical Trials: An Opportunity to Actively Promote Patient-Centered Care
por: Bergerot, Cristiane Decat, et al.
Publicado: (2022)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
por: Marconi, Lorenzo, et al.
Publicado: (2022)

Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney
por: Attawettayanon, Worapat, et al.
Publicado: (2023)

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
por: Takemura, Kosuke, et al.
Publicado: (2022)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative
por: Patel, Amit K., et al.
Publicado: (2021)

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study
por: Pecoraro, Alessio, et al.
Publicado: (2023)

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned
por: Agarwal, Dinesh K., et al.
Publicado: (2023)

Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis
por: Baboudjian, Michael, et al.
Publicado: (2022)

Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative
por: Patel, Amit K., et al.
Publicado: (2020)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
por: Hemminki, Otto, et al.
Publicado: (2020)

In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on (99m)Tc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination
por: Papathomas, Thomas, et al.
Publicado: (2020)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

Randomized Clinical Trial Comparing On-clamp Versus Off-clamp Laparoscopic Partial Nephrectomy for Small Renal Masses (CLOCK II Laparoscopic Study): A Intention-to-treat Analysis of Perioperative Outcomes
por: Bertolo, Riccardo, et al.
Publicado: (2022)

Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature
por: Geertsen, Louise, et al.
Publicado: (2022)

COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
por: Ouzaid, Idir, et al.
Publicado: (2022)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy
por: Drobner, Jake, et al.
Publicado: (2023)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
por: Bergerot, Cristiane Decat, et al.
Publicado: (2023)

Estimated Glomerular Filtration Rate Decline at 1 Year After Minimally Invasive Partial Nephrectomy: A Multimodel Comparison of Predictors
por: Crocerossa, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7vk1reu529plmjkum0f24k3jdb